Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.41 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.41 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.38 |
| ▸ | ACLY | P53396 | 3/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | CCR2 | P41597 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6611536 | 0.92 | SLC40A1 (0.44) | SMN1; SMN2LMNASLC40A1ACLYKDM1A | |
| SCHEMBL6610751 | 0.87 | PFKFB3 (0.46) | SMN1; SMN2LMNAMCOLN3PFKFB3ACLY | |
| SCHEMBL6698387 | 0.85 | PFKFB3 (0.41) | SMN1; SMN2PFKFB3SLC40A1ACLYCCR2 | |
| SCHEMBL6613766 | 0.83 | PFKFB3 (0.37) | SMN1; SMN2LMNAMCOLN3PFKFB3SLC40A1 | |
| SCHEMBL6612001 | 0.83 | PFKFB3 (0.41) | SMN1; SMN2PFKFB3SLC40A1ACLYCCR2 | |
| SCHEMBL6613132 | 0.82 | MCL1 (0.47) | SMN1; SMN2LMNAPFKFB3ALDH1A1MEN1 | |
| SCHEMBL6611498 | 0.81 | PFKFB3 (0.38) | PFKFB3SLC40A1ACLYALDH1A1CCR2 | |
| SCHEMBL6611861 | 0.80 | PFKFB3 (0.43) | SMN1; SMN2LMNAMCOLN3PFKFB3SLC40A1 | |
| SCHEMBL6614194 | 0.79 | CYP2E1 (0.47) | PFKFB3SLC40A1ACLYALDH1A1MEN1 | |
| SCHEMBL6612762 | 0.78 | MAPT (0.41) | SMN1; SMN2PFKFB3SLC40A1ACLYMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004112779-A1 | NEW USE VII | BIOVITRUM AB (SE) | 2004-12-29 | — | — | WO | claimed |
| US-20030130279-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2003-07-10 | — | — | US | claimed |
| WO-2019075394-A1 | COMPOUNDS FOR TREATMENT OF EMOTIONAL/PSYCHOLOGICAL SYMPTOMS IN FRAGILE X SYNDROME | VANDERKLISH PETER (US) | 2019-04-18 | — | — | WO | disclosed |
| WO-2004112779-A1 | NEW USE VII | BIOVITRUM AB (SE) | 2004-12-29 | — | — | WO | disclosed |
| US-20030130279-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130279-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B1, HSD3B1 | SMN1; SMN2 3179/4885LMNA 1976/4885MCOLN3 3966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.